Rare diseases, like M&As and creative collaboration deals before them, present opportunities for pharmas and biotechs to boost their bottom lines, but
there is a risk of tunnel vision (and plenty of precedent for it as well) of which we must remain wary
Decades after the precision medicine revolution began, it is worth assessing whether the evidence still supports genomics as the
primary pillar upon which to understand cancer and make treatment decisions
Biomarkers that are present in body fluids have the potential to form the basis of affordable diagnostic tests to detect diseases in
their earliest stages and monitor disease progression (and allow vital treatment where early intervention is crucial or diagnosis currently difficult), and
neglected tropical diseases are provided here as an example.